TheWealthWeb

Nippon India Pharma Fund Regular Growth

Nippon India Mutual FundEquity Schemes - Sectoral FundRegular · GrowthRisk: Very High3Y rank 35 of 142

NAV ₹585.2465 on 13 November 2026

AMFI name: Nippon India Pharma Fund-Growth Plan-Growth Option · Scheme code 102431 · ISIN INF204K01968

1 year
+13.11%
3 years, a year
+17.50%
5 years, a year
+14.23%
Since 3 Apr 2006, a year
+17.62%
NAV performance, last year

Returns

To 13 November 2026. Up to 1 year: total change. 3 and 5 years: compound return a year.

PeriodThis fundNIFTY HEALTHCARE INDEX TRICategory median
1M+8.65%+8.67%+8.25%
6M+7.40%+12.84%+9.28%
1Y+13.11%+38.92%+4.48%
3Y+17.50%+28.05%+15.37%
5Y+14.23%-+13.85%

Benchmark: NIFTY HEALTHCARE INDEX TRI (total return index), measured over the same dates. The scheme document names BSE Healthcare TRI, which we do not hold, so this is the closest NSE index.

Category median: the middle return among Regular plans (Growth option) in AMFI's “Equity Schemes - Sectoral Fund” category, up to 20 funds with clean data. Ranks are under “Rank among peers”.

Risk

From daily NAVs. Alpha, beta and capture are measured against NIFTY HEALTHCARE INDEX TRI.

Volatility
13.14%
Annualised, 3 years
Max drawdown
-14.84%
Worst fall from a peak, 3 years
Sharpe ratio
0.88
Return above the risk-free rate per unit of volatility, 3 years
Sortino ratio
1.23
Like Sharpe, counting only falls, 3 years
Alpha
+0.15%
Return a year beyond what beta explains, 3 years
Beta
0.53
1.00 moves in step with the benchmark, 3 years
Upside capture
46%
Share of the benchmark's rises captured, 3 years
Downside capture
94%
Share of the benchmark's falls taken (lower is better), 3 years

Every 3-year holding period

Worst
-2.46%
Median
+21.28%
Best
+50.98%
Ended positive
98.1%

Compound return a year for each 3-year window in the NAV history we hold. Less sensitive to the end date than a single 3-year figure.

Rank among peers

Regular plans, Growth option, in AMFI's “Equity Schemes - Sectoral Fund” category. Each rank counts only the peers that have that figure.

Compare with Top Peers
3-Year Return RankQ1
#35of 142
+17.50%
Ahead of 107 of the other 141
Q1
Q2
Q3
Q4
1-Year Return RankQ1
#44of 233
+13.11%
Ahead of 189 of the other 232
Q1
Q2
Q3
Q4
Sharpe (Risk-Adjusted)Q1
#21of 232
0.88
Ahead of 211 of the other 231
Q1
Q2
Q3
Q4
Highest 3-year returns in the categoryRegular plans · Growth option
RankScheme Name3Y Return1Y ReturnSharpeDirect TERAUM
#1
Nippon India Mutual Fund
+46.52%+60.64%1.071.06%₹1,100 Cr
#2
HDFC Mutual Fund
+33.64%+20.34%1.070.89%₹11,128 Cr
#3
HDFC Mutual Fund
+31.28%+31.60%1.761.03%₹3,128 Cr
#4
SBI Mutual Fund
+25.42%+26.07%1.470.76%₹5,565 Cr
#5
HDFC Mutual Fund
+24.77%+10.10%1.091.10%₹1,997 Cr
#6
Mirae Asset Mutual Fund
+24.42%+27.89%1.28-₹3,458 Cr
#7
UTI Mutual Fund
+23.89%+22.00%1.311.35%₹1,399 Cr
#8
ICICI Prudential Mutual Fund
+22.73%+10.29%0.952.08%₹3,926 Cr
#35
Nippon India Pharma FundCurrent Fund
Nippon India Mutual Fund
+17.50%+13.11%0.881.00%₹9,272 Cr

Costs and fund facts

Expense ratio (stated maximum)
Direct 1.00% · Regular 1.84%
Exit load
1% if redeemed or switched out on or before completion of 1 month from the date of allotment of units.Nil, thereafter.
Fund size (all plans)
₹9,272 CrAverage, quarter to September 2026
Benchmark
BSE Healthcare TRICompared here with NIFTY HEALTHCARE INDEX TRI
Allotment date
5 June 2004Scheme document
Type
Open
AMFI scheme code
102431

Fund manager

  • Sailesh Raj Bhan

How each manager has done since taking over: fund manager scorecard.

Investment objective

The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies. There is no assurance that the investment objective of the Scheme will be achieved.

From the scheme summary document filed with AMFI.

SIP calculator

A monthly SIP replayed on this fund's actual daily NAVs: what it would be worth today.

Monthly SIP Amount₹10,000
Investment Horizon5 Years
Simulating monthly 1st from 15 Nov 2021 to 13 Nov 2026
Total Invested61 mos
₹6,10,000
Units: 1,589.138
Current Portfolio Value
₹9,30,038
At latest recorded NAV
Total Profit
+₹3,20,038
+52.5% absolute return
SIP XIRR
16.91%
Annualised, money-weighted
Wealth CompositionProfit is 52% of total invested capital
Invested: ₹6,10,000Profit Generated: ₹3,20,038
Same SIP in the benchmark (NIFTY HEALTHCARE INDEX TRI)Same dates & amounts
Scheme SIP Valuation
₹9,30,038
16.9% XIRR
Benchmark SIP Valuation
₹5,56,767
25.8% XIRR
Fund minus benchmark
+₹3,73,271
Over 61 monthly installments
SIP instalments are bought on the first NAV date of each month; values use the latest NAV we hold. Past returns are not a guide to future returns.

About this fund

Nippon India Pharma Fund Regular Growth is a mutual fund scheme from Nippon India Mutual Fund, listed by AMFI under “Equity Schemes - Sectoral Fund”. This page covers the Regular plan with the Growth option. Its NAV was ₹585.2465 on 13 November 2026. It returned 13.11% over 1 year, 17.50% a year over 3 years and 14.23% a year over 5 years, measured from NAVs (3- and 5-year figures are annualised). Its benchmark, NIFTY HEALTHCARE INDEX TRI, returned 28.05% a year over 3 years. Its 3-year return ranks #35 of 142 Regular Growth plans in the same AMFI category. Q-Score: 76 out of 100, rated only against funds in the same category. The fund house rates its risk as “Very High” on the SEBI riskometer. Its average assets under management were ₹9,272 Cr across all plans for the quarter ending September 2026, as reported to AMFI. Its scheme summary document states a maximum expense ratio (TER) of 1.84% a year for the Regular plan. Managed by Sailesh Raj Bhan. Its scheme summary document gives the allotment date as 5 June 2004.

Figures are calculated from AMFI NAVs and index data, not taken from fund factsheets. Methodology. Past performance is not a guide to future returns.

Plans and options of this fund (5)

PlanOptionISINAMFI codeNAV
RegularThis pageGrowthINF204K01968102431₹585.2513 Nov 2026
DirectGrowthINF204K01I50118759₹659.4813 Nov 2026
DirectIDCWINF204K01I43118756₹180.4813 Nov 2026
RegularIDCW-102433₹126.3813 Nov 2026
DCW Plan ReinvestmentIDCWINF204K01943--